Small‐cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first‐line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.

中文翻译：

---

小细胞肺癌发展和治疗的新见解。

小细胞肺癌（SCLC）约占肺癌病例的15％；然而，它的特点是容易复发和低存活率，是临床上最难治的疾病之一。尽管进行了数十年的基础和临床研究，但SCLC的管理进展甚微。目前，SCLC的标准一线治疗方案仍然是顺铂或卡铂联合依托泊苷，化疗的不良反应绝不能忽略。此外，SCLC的免疫疗法仍处于早期阶段，迫切需要新的研究。在这篇综述中，我们描述了小细胞肺癌的发展和当前的治疗方法，旨在为基础研究和临床策略提供有用的建议。